文献速递产科母胎医学

对有早产症状女性进行宫颈长度测量和胎儿纤连蛋白检测的诊断策略的成本效益

Cost-effectiveness of diagnostic testing strategies including cervical-length measurement and fibronectin testing in women with symptoms of preterm labor.
PubMed 文献 · Ultrasound Obstet Gynecol · 2018-03-30

本研究基于模型评估有早产症状女性中七种基于宫颈长度和/或胎儿纤连蛋白检测的策略的成本效益,采用社会视角并加权新生儿结局和费用。当宫颈长度15-30 mm时加做胎儿纤连蛋白检测被认为具有成本效益,与全部治疗策略相比每名女性节省€3919,但每万名有早产征兆女性中增加1例围产期死亡和21例不良结局。在荷兰实施该策略每年可节省€2.4百万至€7.6百万。

要点

  • 当宫颈长度15-30 mm时加做胎儿纤连蛋白检测具有成本效益,每名女性节省€3919。
  • 该策略每万名有早产征兆女性中增加1例围产期死亡和21例不良结局。
  • 在荷兰实施该策略每年可节省€2.4百万至€7.6百万。

核心结论

  • 对于24-34周妊娠有早产症状的女性,当宫颈长度在15-30 mm之间时加做胎儿纤连蛋白检测是一种可行且节省成本的策略。

研究设计与样本

  • 基于模型的成本效益分析,评估七种基于宫颈长度测量和/或胎儿纤连蛋白检测的检测-治疗策略,采用社会视角,对新生儿结局和费用进行加权,疾病患病率、检测准确性和费用的估计基于荷兰最近开展的两项全国性队列研究。

主要发现

  • 单独使用胎儿纤连蛋白检测或宫颈长度测量预测早产的策略,与联合使用两种检测的策略相比,费用更高且不良新生儿结局发生率更高。
  • 当宫颈长度为15-30 mm时加做胎儿纤连蛋白检测被认为具有成本效益,与全部治疗策略相比每名女性节省€3919,但新生儿健康结局略有恶化,即每万名有早产征兆女性中增加1例围产期死亡和21例不良结局(增量成本效益比分别为€39百万和€1.9百万)。
  • 在荷兰(每年约180 000次分娩)实施该策略,每年可节省€2.4百万至€7.6百万,新生儿健康结局仅略有恶化。

关键数值与推荐

  • 当宫颈长度为15-30 mm时加做胎儿纤连蛋白检测,与全部治疗策略相比每名女性节省€3919。
  • 该策略每万名有早产征兆女性中增加1例围产期死亡和21例不良结局,增量成本效益比分别为€39百万和€1.9百万。
  • 在荷兰实施该策略每年可节省€2.4百万至€7.6百万。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the cost-effectiveness of combining cervical-length (CL) measurement and fetal fibronectin (fFN) testing in women with symptoms of preterm labor between 24 and 34 weeks' gestation. METHODS: This was a model-based cost-effectiveness analysis evaluating seven test-treatment strategies based on CL measurement and/or fFN testing in women with symptoms of preterm labor from a societal perspective, in which neonatal outcomes and costs were weighted. Estimates of disease prevalence, test accuracy and costs were based on two recently performed nationwide cohort studies in The Netherlands. RESULTS: Strategies using fFN testing and CL measurement separately to predict preterm delivery are associated with higher costs and incidence of adverse neonatal outcomes compared with strategies that combine both tests. Additional fFN testing when CL is 15-30 mm was considered cost effective, leading to a cost saving of €3919 per woman when compared with a treat-all strategy, with a small deterioration in neonatal health outcomes, namely one additional perinatal death and 21 adverse outcomes per 10 000 women with signs of preterm labor (incremental cost-effectiveness ratios €39 million and €1.9 million, respectively). Implementing this strategy in The Netherlands, a country with about 180 000 deliveries annually, could lead to an annual cost saving of between €2.4 million and €7.6 million, with only a small deterioration in neonatal health outcomes. CONCLUSION: In women with symptoms of preterm labor at 24-34 weeks' gestation, performing additional fFN testing when CL is between 15 and 30 mm is a viable and cost-saving strategy. Copyright © 2017 ISUOG. Published by John Wiley & Sons Ltd.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. van Baaren GJ, Vis JY, Wilms FF, et al. Cost-effectiveness of diagnostic testing strategies including cervical-length measurement and fibronectin testing in women with symptoms of preterm labor. Ultrasound Obstet Gynecol. 2018. PMID: 28370518. doi:10.1002/uog.17481

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。